Girard Partners’s Cardiff Oncology CRDF Stock Holding History

Girard Partners’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-11	Closed	–	–	356
2018 Q3	$0	Buy	+11	New	+$52	﹤0.01%	944

Other funds holding CRDF

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Dowling & Yahnke San Diego, California $2.15B AUM 10.82% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

SNB

Security National Bank Omaha, Nebraska $838M AUM 39.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Girard Partners's CRDF Position: Q4 2018 in Review

Girard Partners sold out of Cardiff Oncology (CRDF) in Q4 2018, closing a stake of 11 shares.

Girard Partners first reported a position in CRDF in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 26 funds tracked by Wall St. Rank hold CRDF as of Q4 2018.

Girard Partners reported no remaining Cardiff Oncology position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 11 Cardiff Oncology shares in Q4 2018.
Girard Partners first reported a position in Cardiff Oncology in Q3 2018 and held it in 1 quarter.
Girard Partners's Cardiff Oncology position peaked at $0 in Q3 2018.
26 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.